ZAI LAB LIMITED Increase (Decrease) in Prepaid Expense and Other Assets
ZAI LAB LIMITED (ZLAB) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$4.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- ZAI LAB LIMITED increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$3.20M.
- ZAI LAB LIMITED increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.52M, a 194.82% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$6.85M, a 186.01% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $2.64M, a 80.25% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$5.06M, a 127.01% decline from fiscal 2024.
- ZAI LAB LIMITED increase (decrease) in prepaid expense and other assets for fiscal 2024 was $18.73M.
- ZAI LAB LIMITED increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$12.25M, a 163.59% decline from fiscal 2022.
- ZAI LAB LIMITED increase (decrease) in prepaid expense and other assets for fiscal 2022 was $19.26M, a 171.78% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.72M 10-Q · filed 2026-08-06 | -$11.57M derived: sum of 3 quarters · filed 2026-08-06 | -$8.92M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$1.52M 10-Q · filed 2026-05-07 | -$8.37M derived: sum of 2 quarters · filed 2026-05-07 | -$5.72M derived: sum of 3 quarters · filed 2026-05-07 | -$8.18M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$6.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$4.21M derived: sum of 2 quarters · filed 2026-02-26 | -$6.66M derived: sum of 3 quarters · filed 2026-08-06 | -$5.06M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $188.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.79M 10-Q · filed 2025-11-06 | $9.75M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$854.00K 10-Q · filed 2026-08-06 | $7.11M derived: sum of 3 quarters · filed 2026-08-06 | $20.49M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.60M 10-Q · filed 2026-05-07 | $9.56M derived: sum of 2 quarters · filed 2026-05-07 | $22.94M derived: sum of 3 quarters · filed 2026-05-07 | $19.08M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.34M derived: sum of 2 quarters · filed 2026-02-26 | $17.48M derived: sum of 3 quarters · filed 2026-02-26 | $18.73M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $13.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.51M derived: sum of 2 quarters · filed 2025-11-06 | $10.77M 10-Q · filed 2025-11-06 | $3.65M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | -$3.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.61M 10-Q · filed 2025-08-07 | -$9.73M derived: sum of 3 quarters · filed 2026-02-26 | -$14.77M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $1.25M 10-Q · filed 2025-05-08 | -$5.87M derived: sum of 2 quarters · filed 2026-02-26 | -$10.91M derived: sum of 3 quarters · filed 2026-02-26 | -$17.46M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | -$7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$12.16M derived: sum of 2 quarters · filed 2026-02-26 | -$18.72M derived: sum of 3 quarters · filed 2026-02-26 | -$12.25M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | -$5.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$11.60M derived: sum of 2 quarters · filed 2024-11-12 | -$5.13M 10-Q · filed 2024-11-12 | $8.27M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | -$6.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$87.00K 10-Q · filed 2024-08-06 | $13.31M derived: sum of 3 quarters · filed 2025-02-27 | $19.22M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $6.47M 10-Q · filed 2024-05-08 | $19.87M derived: sum of 2 quarters · filed 2025-02-27 | $25.78M derived: sum of 3 quarters · filed 2025-02-27 | $27.26M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $13.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $19.31M derived: sum of 2 quarters · filed 2025-02-27 | $20.79M derived: sum of 3 quarters · filed 2025-02-27 | $19.26M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $5.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.39M derived: sum of 2 quarters · filed 2023-11-07 | $5.86M 10-Q · filed 2023-11-07 | $6.80M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$48.00K 10-Q · filed 2023-08-07 | $896.00K derived: sum of 3 quarters · filed 2024-02-27 | $5.08M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | -$1.53M 10-Q · filed 2023-05-09 | -$587.00K derived: sum of 2 quarters · filed 2024-02-27 | $3.60M derived: sum of 3 quarters · filed 2024-02-27 | $2.17M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $944.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $5.13M derived: sum of 2 quarters · filed 2024-02-27 | $3.70M derived: sum of 3 quarters · filed 2024-02-27 | $7.09M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $4.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.76M derived: sum of 2 quarters · filed 2022-11-09 | $6.14M 10-Q · filed 2022-11-09 | $6.78M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.95M 10-Q · filed 2022-08-09 | $1.95M 10-Q · filed 2021-08-09 | $2.59M derived: sum of 3 quarters · filed 2023-03-01 | $5.20M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $3.39M 10-Q · filed 2022-05-10 | $4.02M derived: sum of 2 quarters · filed 2023-03-01 | $6.64M derived: sum of 3 quarters · filed 2023-03-01 | $6.21M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $635.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.25M derived: sum of 2 quarters · filed 2023-03-01 | $2.82M derived: sum of 3 quarters · filed 2023-03-01 | $4.20M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $2.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $2.19M derived: sum of 2 quarters · filed 2021-11-09 | $3.56M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | -$427.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $948.00K 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | $1.38M 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | $1.13M 10-K · filed 2022-03-01 | |||||
| 2019-06-30 | $361.00K 6-K · filed 2020-09-11 | |||||
| 2018-12-31 | $4.79M 10-K · filed 2021-03-01 | $4.79M 20-F · filed 2019-03-29 | ||||
| 2017-12-31 | $811.00K 20-F · filed 2020-04-29 | $810.98K 20-F · filed 2018-04-30 | ||||
| 2016-12-31 | $74.51K 20-F · filed 2019-03-29 | |||||
| 2015-12-31 | -$33.71K 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |